Risk factor
Good trading liquidity
Profitability factor
Greatly overvalued vs peers
About
Established in 2001 and headquartered in Shenzhen, China, Chipscreen Biosciences specializes in the discovery, development, and commercialization of innovative small-molecule pharmaceuticals. The company cultivates a pipeline of novel drug candidates and precursor compounds, all of which are progressing through diverse research phases and are protected by extensive global intellectual property rights. Its key therapeutic areas of focus encompass oncology, metabolic disorders, and autoimmune conditions.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITD.